Home › Neuroendocrine Carcinoma › Tennessee › Nashville
Neuroendocrine Carcinoma clinical trials in Nashville, TN
3 studies for Neuroendocrine Carcinoma are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RecruitingPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RecruitingPhase 1/2
- Sarah Cannon Research Institute - Oncology Partners, Nashville
Neuroendocrine Carcinoma trials in other cities
- Houston, TX6 studies
- New York City, NY6 studies
- Arlington, VA5 studies
- Dallas, TX4 studies
- Los Angeles, CA4 studies
- Washington, DC4 studies
- St. Louis, MO3 studies
- Columbus, OH3 studies
- Grand Rapids, MI3 studies
- Atlanta, GA3 studies
- New Haven, CT3 studies
- Denver, CO3 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.